VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer’s syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Learn more about RetinalGenix Technologies Inc's (RTGN) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Eunice Kim
Financial Summary
Share Statistics
RTGN
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$75.2
$389.6
19%
Shares Out (Mil)
18.8
40.9
29%
Institutional Ownership
na
82.8%
na
Float (Mil)
na
35.5
na
Beta
-3.32
0.85
0%
Avg Daily Volume (000s)
3
298
11%
Price Change (52-week)
na
63.7%
na
Growth
RTGN
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
11.8%
na
Net Income (5yr)
(2.7%)
(5.6%)
36%
EPS (5yr)
(20.3%)
10.2%
13
Dividends (5yr)
na
0.0%
na
Cash Flow (5yr)
0.0%
(15.5%)
64%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
na
na
na
Current EPS
na
na
na
Month Ago EPS
na
na
na
# Rev Up
na
na
na
# Rev Down
na
na
na
Three Months Ago EPS
na
na
na
Year/Year Chg
na
na
na
Financials
RTGN
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
na
$141
na
Net Income (TTM) (Mil)
($2)
($9)
36%
EPS (TTM)
($0.112)
($0.400)
36%
Operating Cash Flow (TTM) (Mil)
($1)
($2)
31%
Net Cash Flow (TTM) (Mil)
na
$1
na
Long-Term Debt (Q1) (Mil)
$0
$26
0%
Enterprise Value (Q1) (Mil)
na
$409
na
Valuation
RTGN
Industry Median
Percentile (All Stocks)
P/B
na
2.73
na
P/E
na
25.0
na
Dividend Yield
na
0.0%
na
PEG (5yr hist)
na
1.4
na
Ratios
RTGN
Industry Median
Percentile (All Stocks)
Gross Margin
na
58.7%
na
Net Margin
na
(6.9%)
na
ROA
na
(12.2%)
na
ROE
90.4%
(10.7%)
96%
Liabilities to Assets
na
47.2%
na
F-Score
1
4
1%
RetinalGenix Technologies Inc. did not pass any screens on 10/2/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors